Generated by AI
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease and Parkinson’s disease, with additional programs targeting traumatic brain injury, stroke, Lewy body dementia, and advanced Alzheimer’s disease. The company’s lead candidate, buntanetap, is being studied for chronic neurodegeneration, while ANVS405 and ANVS301 extend its research into acute and later-stage neurological conditions. Annovis Bio’s work is directed at central nervous system disorders where protein misfolding, neuroinflammation, and cognitive decline play key roles. Based in Malvern, Pennsylvania, Annovis Bio operates as a research-driven drug development company within the biotechnology sector.
Website101 Lindenwood Drive
Malvern, PA, 19355
United States
The latest articles about ANVS.
MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, a
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through th...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Feb 5's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about ANVS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.